Recent Updates
Recently added Catalysts

Autoimmune Pulmonary Alveolar Proteinosis: one US-listed biotech with a clinical-stage programme

Immunology & InflammationUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$1.1Buniverse median $1.20B
Allocated capital$1.1B$1.1B competing
Phase 3 or filed10 mid, 0 early
Pure plays1this indication only
Capital rank143/299crowding rank 157

Autoimmune Pulmonary Alveolar Proteinosis is uncontested. Savara (SVRA) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Molgramostim in phase 3.

There is no public comparable to price it against, and SVRA runs clinical programmes in this indication and nothing else, so its $1.1B market cap is a direct read on what the market thinks this programme is worth.

The one programme here is in late-stage development, with 1 dated catalyst in the next 12 months.

$1.1B of allocated capital sits in Autoimmune Pulmonary Alveolar Proteinosis, ranking it 143rd of 299 indications by the money committed to it.

Companies developing drugs for Autoimmune Pulmonary Alveolar Proteinosis 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
SVRASavaraMolgramostimPhase 32$1.1BYes1 30 Sep 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Autoimmune Pulmonary Alveolar Proteinosis counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Autoimmune Pulmonary Alveolar Proteinosis has one competitor and a median of $1.1B.

Immunology & Inflammation

Immunology & Inflammation holds $139B of the map's capital, 20.7% of the total, spread across 51 indications and 82 companies. 23 of those indications have more than one company competing.

See every Immunology & Inflammation indication on the map

Related indications in Immunology & Inflammation

Chronic Spontaneous Urticaria1 company · $1.0B · median $3.1BUncontestedPruritus2 companies · $1.2B · median $1.6BConcentrated betEosinophilic Esophagitis2 companies · $1.2B · median $610MOrphan cornerModerate to Severe Atopic Dermatitis1 company · $1.3B · median $2.6BUncontestedPeanut Allergy1 company · $861M · median $861MUncontestedCeliac Disease1 company · $788M · median $1.6BUncontestedChronic Granulomatous Disease1 company · $673M · median $673MUncontestedAcne1 company · $673M · median $673MUncontested

Autoimmune Pulmonary Alveolar Proteinosis pipeline questions

Which biotech companies are developing drugs for Autoimmune Pulmonary Alveolar Proteinosis?

Savara (SVRA, Molgramostim, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Autoimmune Pulmonary Alveolar Proteinosis.

How advanced is the Autoimmune Pulmonary Alveolar Proteinosis pipeline?

Of the 1 clinical-stage programme in Autoimmune Pulmonary Alveolar Proteinosis, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Autoimmune Pulmonary Alveolar Proteinosis?

No. SVRA is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Autoimmune Pulmonary Alveolar Proteinosis, which is why the indication is classified as uncontested.

When is the next Autoimmune Pulmonary Alveolar Proteinosis catalyst?

The next dated catalyst in Autoimmune Pulmonary Alveolar Proteinosis is SVRA on 30 Sep 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map